51410-08-3

Upstream product

• 75-36-5 acetyl chloride 
• 588-16-9 m-methoxyacetanilide 
• 58487-62-0 1-acetyl-3-(3-methoxyphenyl)urea 
• 75-15-0 carbon disulfide 
• 7446-70-0 aluminium trichloride 
• 591-27-5 m-Hydroxyaniline 
• 40547-58-8 N-(4-acetyl-3-hydroxyphenyl)acetamide 
• 74-88-4 methyl iodide 
• 621-42-1 meta-hydroxyacetanilide 
• 6317-89-1 3-acetamidophenyl acetate 
• 77-78-1 dimethyl sulfate 
• 74-83-9 methyl bromide 

Downstream Products

• 865306-00-9 N-[4-(1-Hydroxy-1-methyl-ethyl)-3-methoxy-phenyl]-acetamide 
• 1448349-19-6 (E)-1-(4-amino-2-methoxyphenyl)-3-(naphthalen-2-yl)-prop-2-en-1-one 
• 1448349-20-9 (E)-1-(4-amino-2-methoxyphenyl)-3-(5-methylfuran-2-yl)-prop-2-en-1-one 
• 1448349-21-0 (E)-1-(4-amino-2-methoxyphenyl)-3-(5-methylthiophen-2-yl)prop-2-en-1-one 
• 60207-18-3 4'-amino-2'-methoxylacetophenone 

Relevant academic research and scientific papers

Synthesis and identification of new flavonoids targeting liver X receptor β involved pathway as potential facilitators of Aβ clearance with reduced lipid accumulation

Alzheimer's disease (AD) is associated with impaired Aβ degradation in the brain. Enhancing the process of Aβ clearance is an attractive potential AD therapy. Treatment with LXR agonists may reduce Aβ levels in vivo. However, the clinical potential of man

Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases

Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

Diaminopyrimidines as P2X3 and P2X2/3 antagonists

Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

Central Nervous System Active Compounds. XIV On the Cyclization of N-Acyl-N'-arylureas

The cyclization of N-acyl-N'-arylureas in polyphosphoric acid has been reinvestigated.The product is not only the 4-substituted quinazolin-2(1H)-one as reported, but also contains the 2-acylaniline in major proportions.Two minor products have also been isolated.At 80 deg, an intermediate has been detected, the properties of which are consistent with it being the corresponding 2-acylphenylurea.Acyl ureas with strongly electron-withdrawing acyl groups from major amount of the corresponding anilide by the formal loss of cyanic acid.The application of this reaction tothe synthesis of quinazolinylphthalides has been investigated.